Nabi Shahzaib, Kessler Elizabeth R, Bernard Brandon, Flaig Thomas W, Lam Elaine T
Division of Medical Oncology, Anschutz Medical Campus, University of Colorado Denver, Aurora, CO, USA.
F1000Res. 2018 Mar 12;7:307. doi: 10.12688/f1000research.13179.1. eCollection 2018.
Over the past decade, our understanding of the biology and pathophysiology of renal cell carcinoma (RCC) has improved significantly. Insight into the disease process has helped us in developing newer therapeutic approaches toward RCC. In this article, we review the various genetic and immune-related mechanisms involved in the pathogenesis and development of this cancer and how that knowledge is being used to develop therapeutic targeted drugs for the treatment of RCC. The main emphasis of this review article is on the most common genetic alterations found in clear cell RCC and how various drugs are currently targeting such pathways. This article also looks at the role of the immune system in allowing the growth of RCC and how the immune system can be manipulated to reactivate cytotoxic immunity against RCC.
在过去十年中,我们对肾细胞癌(RCC)生物学和病理生理学的理解有了显著提高。对疾病过程的深入了解有助于我们开发针对RCC的更新治疗方法。在本文中,我们回顾了参与这种癌症发病机制和发展的各种遗传和免疫相关机制,以及这些知识如何被用于开发治疗RCC的靶向治疗药物。这篇综述文章的主要重点是在透明细胞RCC中发现的最常见遗传改变,以及目前各种药物如何靶向这些途径。本文还探讨了免疫系统在允许RCC生长中的作用,以及如何操纵免疫系统以重新激活针对RCC的细胞毒性免疫。